Page 14«..10..13141516..2030..»

Category Archives: Global News Feed

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Posted: April 3, 2025 at 2:45 am

See original here:
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Posted in Global News Feed | Comments Off on eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Posted: April 3, 2025 at 2:45 am

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United States Food and Drug Administration (FDA) to discuss the accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation.

Excerpt from:
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

Posted in Global News Feed | Comments Off on Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure

NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Posted: April 3, 2025 at 2:45 am

Conference call and webcast scheduled for April 3, 2025 at 8:00 A.M. EDT / 2:00 P.M. CEST

Go here to read the rest:
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Posted in Global News Feed | Comments Off on NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Posted: April 3, 2025 at 2:45 am

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.

See the original post:
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Posted in Global News Feed | Comments Off on Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria…

Posted: April 3, 2025 at 2:45 am

Ad hoc announcement pursuant to Art. 53 LR

Continued here:
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria...

Posted in Global News Feed | Comments Off on Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria…

Veteran Banker Joins Avextra’s Supervisory Board 

Posted: April 3, 2025 at 2:45 am

Go here to read the rest:
Veteran Banker Joins Avextra’s Supervisory Board 

Posted in Global News Feed | Comments Off on Veteran Banker Joins Avextra’s Supervisory Board 

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Posted: April 3, 2025 at 2:45 am

Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website.

Original post:
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Posted in Global News Feed | Comments Off on Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Posted: April 3, 2025 at 2:45 am

Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Here is the original post:
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Posted in Global News Feed | Comments Off on Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines

Novo Nordisk announces changes in Executive Management

Posted: April 3, 2025 at 2:45 am

Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management.

See the article here:
Novo Nordisk announces changes in Executive Management

Posted in Global News Feed | Comments Off on Novo Nordisk announces changes in Executive Management

LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics

Posted: April 3, 2025 at 2:45 am

Press release

See the original post here:
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics

Posted in Global News Feed | Comments Off on LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics

Page 14«..10..13141516..2030..»